8-K: Roivant Reports Q4 FY26 Results, Clinical Updates

Roivant Sciences announced fourth quarter and fiscal year 2026 financial results, highlighting significant clinical trial progress and a major litigation settlement.

Summary

• Roivant Sciences reported financial results for the fourth quarter and fiscal year ended March 31, 2026.
• The company achieved a $2.25 billion global settlement with Moderna, resolving patent-infringement litigation.
• IMVT-1402 showed promising response rates in a rheumatoid arthritis trial, with further updates expected.
• Brepocitinib received Breakthrough Therapy Designation for cutaneous sarcoidosis and is progressing in other indications.
• Commercial launch for brepocitinib in dermatomyositis is anticipated by September 2026.
• Mosliciguat's Phase 2 trial in PH-ILD completed enrollment, with data expected in late 2026.
• Roivant ended the fiscal year with $4.3 billion in cash, cash equivalents, and marketable securities.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report driven by a significant litigation settlement and promising clinical trial data, although increased R&D spending and the discontinuation of batoclimab development temper the overall sentiment.

Positives

• Secured a $2.25 billion global settlement with Moderna, ending patent litigation.
• IMVT-1402 demonstrated clinically meaningful response rates (72.7% ACR20) in difficult-to-treat rheumatoid arthritis.
• Brepocitinib received FDA Breakthrough Therapy Designation for cutaneous sarcoidosis.
• Positive Phase 2 data for brepocitinib in cutaneous sarcoidosis showed significant improvements.
• Commercial launch of brepocitinib in dermatomyositis is expected by the end of September 2026.
• Strong cash position of $4.3 billion as of March 31, 2026, providing runway into profitability.
• Enrollment completed for mosliciguat Phase 2 PHocus study in PH-ILD within one year.

Negatives

• Research and development expenses increased by $53.7 million in Q4 FY26 and $131.4 million for the full year FY26.
• General and administrative expenses increased by $11.2 million in Q4 FY26 and $19.1 million for the full year FY26.
• Discontinued further development of batoclimab across all indications following negative Phase 3 results in thyroid eye disease.
• Loss from continuing operations, net of tax was $397.9 million for the year ended March 31, 2026.

Risks

• Potential for delays in clinical trial readouts or regulatory approvals.
• Uncertainty in the resolution of Moderna's Section 1498 appeal for the remaining $1.3 billion settlement payment.
• Competition in the biopharmaceutical market.
• The company operates in a rapidly changing environment where new risks emerge.

Future Outlook

Roivant anticipates several key clinical readouts and milestones in the second half of calendar year 2026, including further updates on IMVT-1402 in D2T RA, topline data for IMVT-1402 in CLE, and topline data for mosliciguat in PH-ILD. Brepocitinib is expected to launch commercially in dermatomyositis by the end of September 2026, with Phase 3 trials in cutaneous sarcoidosis planned for the second half of 2026, and topline data for brepocitinib in non-infectious uveitis also expected in the second half of 2026. Topline data for IMVT-1402 in Graves disease and myasthenia gravis are expected in calendar year 2027.

Management Comments

• "The positive Period 1 data from the IMVT-1402 trial in D2T RA demonstrate exciting potential for a new, differentiated mechanism to treat RA patients who have failed multiple prior therapies," said Matt Gline, CEO of Roivant.
• "Receiving Breakthrough Therapy Designation from the FDA for brepocitinib in cutaneous sarcoidosis underscores the potentially meaningful opportunity that program could represent for patients in need."
• "I am looking forward to building on this momentum in the second half of 2026, with brepocitinib expected to launch in DM by the end of September, and a number of upcoming clinical readouts, including data in NIU, CLE and PH-ILD, and further updates from the D2T RA trial later this year."

Industry Context

StockSavvy.ai notes that Roivant's diverse pipeline across multiple therapeutic areas, coupled with significant litigation settlements and strong cash reserves, positions it to navigate the competitive biopharmaceutical landscape. The company's strategy of creating nimble subsidiaries (Vants) allows for focused development and commercialization efforts.

Comparison to Industry Standards

• The ACR20, ACR50, and ACR70 response rates of 72.7%, 54.5%, and 35.8% for IMVT-1402 in difficult-to-treat RA at Week 16 are competitive, though direct comparisons require further data from ongoing trials and against established therapies like TNF inhibitors or JAK inhibitors.
• The $2.25 billion settlement with Moderna is a substantial financial event, comparable to other major intellectual property dispute resolutions in the pharmaceutical sector, such as those involving large patent portfolios or blockbuster drug litigation.
• The increase in R&D spending aligns with industry trends for companies advancing multiple late-stage clinical candidates, reflecting the high cost of drug development.

Legal Proceedings

• Global settlement reached with Moderna for $2.25 billion, ending patent-infringement litigation.
• Claim construction ruling in Genevant and Arbutus' lawsuit against Pfizer and BioNTech for patent infringement in the manufacture and sale of their Covid-19 vaccine was favorable.

Stakeholder Impact

• Shareholders: Positively impacted by the significant litigation settlement and promising clinical trial updates, offset by increased R&D expenses.
• Employees: Increased R&D and G&A expenses may reflect continued investment in personnel and operations.
• Creditors: The strong cash position of $4.3 billion provides financial stability.

Next Steps

• Provide further updates on the IMVT-1402 program in the second half of calendar year 2026.
• Initiate a Phase 3 program for brepocitinib in cutaneous sarcoidosis in the second half of calendar year 2026.
• Report topline data from the Phase 3 trial of brepocitinib in NIU in the second half of calendar year 2026.
• Report topline data from the IMVT-1402 proof-of-concept trial in CLE in the second half of calendar year 2026.
• Report topline data from the mosliciguat Phase 2 trial in PH-ILD in the second half of calendar year 2026.
• Report topline data from potentially registrational trials of IMVT-1402 in GD and MG in calendar year 2027.

Key Dates

Recommendation

The company has a strong cash position and promising clinical data for key pipeline assets, alongside a significant litigation settlement. However, the increased R&D spend, discontinuation of batoclimab, and the need for further clinical validation and regulatory approvals warrant a cautious 'hold' rating until more definitive commercial or clinical milestones are achieved.

Keywords

Roivant Sciences, Financial Results, Clinical Trials, IMVT-1402, Brepocitinib, Rheumatoid Arthritis, Cutaneous Sarcoidosis, Moderna Settlement